Gilead Sciences stock gains fresh support from HIV prevention data

Gilead Sciences reported fresh evidence for its long-acting HIV prevention strategy as the HIV Glasgow 2026 congress moves toward its final day. In a November 6 release, Gilead Sciences said the Phase 2 PURPOSE 5 study showed stronger one-year persistence for twice-yearly injectable lenacapavir than for daily oral emtricitabine/tenofovir disoproxil fumarate, or F/TDF.

Gilead said the study enrolled people in the United Kingdom and France who could benefit from pre-exposure prophylaxis but were not taking PrEP at enrollment. The results are being presented at HIV Glasgow, which runs through Wednesday, November 11.

Persistence is the central investment signal

At Week 52, 85.6 percent of participants receiving lenacapavir remained persistent on PrEP, compared with 46.3 percent in the daily F/TDF group. Gilead reported no HIV acquisitions among participants receiving lenacapavir; one occurred in the F/TDF group, with drug-level analysis consistent with fewer than two doses per week at diagnosis.

The findings matter commercially because adherence remains a major constraint on the real-world effectiveness of daily prevention. A six-month dosing schedule could improve continuity for some patients, although uptake will depend on clinical practice, access, pricing and the long-term safety profile.

Gilead Sciences stock traded at 151.69 euros on Lang & Schwarz at 17:00 CET on Tuesday, November 10, 2026.

Pipeline breadth remains in focus

PURPOSE 5 is one part of a broader HIV program that Gilead is highlighting at the congress. The company is also presenting evidence involving Biktarvy, a daily bictegravir and lenacapavir combination, an investigational once-weekly regimen and early work on a potential twice-yearly injectable treatment.

For investors, the next questions are whether the persistence advantage translates into durable demand and how the newer regimens fit within Gilead's existing HIV portfolio. The latest study adds clinical support to the long-acting strategy but does not by itself establish future sales.

Broader market sentiment can be followed through the S&P 500.

More news and analyses are available on Gilead Sciences stock.